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Sepsis and septic shock, caused by an excessive systemic host-inflammatory response, are associated with high morbidity and mor-
tality. The complement system and TLRs provide important pattern recognition receptors initiating the cytokine storm by extensive
cross-talk. We hypothesized that double blockade of complement C5 and the TLR coreceptor CD14 could improve survival of
experimental polymicrobial sepsis. Mice undergoing cecal ligation and puncture (CLP)–induced sepsis were treated with neu-
tralizing anti-CD14 Ab biG 53, complement C5 inhibitor coversin (Ornithodoros moubata C inhibitor), or a combination thereof.
The inflammatory study (24-h observation) revealed statistically significant increases in 22 of 24 measured plasma biomarkers in
the untreated CLP group, comprising 14 pro- and anti-inflammatory cytokines and 8 chemokines, growth factors, and granulocyte
activation markers. Single CD14 or C5 blockade significantly inhibited 20 and 19 of the 22 biomarkers, respectively. Combined
CD14 and C5 inhibition significantly reduced all 22 biomarkers (mean reduction 85%; range 54–95%) compared with the
untreated CLP group. Double blockade was more potent than single treatment and was required to significantly inhibit IL-6
and CXCL1. Combined inhibition significantly reduced morbidity (motility and eyelid movement) and mortality measured over
10 d. In the positive control CLP group, median survival was 36 h (range 24–48 h). Combined treatment increased median
survival to 96 h (range 24–240 h) (p = 0.001), whereas survival in the single-treatment groups was not significantly increased
(median and range for anti-CD14 and anti-C5 treatment were 36 h [24–48 h] and 48 h [24–96 h]). Combined with standard
intervention therapy, specific blockade of CD14 and C5 might represent a promising new therapeutic strategy for treatment of
polymicrobial sepsis. The Journal of Immunology, 2014, 192: 5324–5331.
S
epsis and septic shock, caused by an excessive host in-
flammatory response to infections, burns, or trauma, are
associated with high morbidity and mortality. Worldwide,
millions of deaths each year are attributable to sepsis. The inci-
dence of sepsis is increasing, and it is one of the largest global
health economic burdens (1). Early goal-directed resuscitation and
administration of antibiotics have improved patient outcomes, but
specific therapy has still not been developed (2, 3). Various ther-
apeutic approaches, including attenuation of the detrimental host
inflammatory response, have proven clinically ineffective (4). The
sole exception, drotrecogin alfa activated protein C, which had
Food and Drug Administration approval for treatment of sepsis,
has recently been withdrawn, adding to the long list of unsuc-
cessful interventions using single drugs (5).
Recently, issues related to management of sepsis were read-
dressed, identifying a pressing need to develop effective drugs and
define new therapeutic approaches (6–9). In the current study, we
demonstrate the efficacy of an intervention principle for sepsis
based on the hypothesis that combined inhibition of key upstream
sensor and effector systems of innate immunity will attenuate the
initial development of uncontrolled systemic inflammation (10, 11).
Specifically, double blockade of complement component C5 and the
TLR family molecule CD14 was investigated in the clinically rel-
evant cecal ligation and puncture (CLP) mouse model of sepsis (12).
CD14 is a promiscuous binding protein primarily known as an
accessory molecule facilitating LPS transfer from LPS-binding
protein to TLR4–MD2 complexes, thereby increasing sensitivity
toward LPS, which is a major cell wall component of Gram-
negative bacteria (13, 14). CD14 also recognizes a variety of
other exogenous and endogenous molecular patterns and is in-
volved in signaling through TLR2, TLR3, TLR7, and TLR9 (15),
which are activated by a variety of ligands associated with Gram-
positive bacteria, fungi, viruses, and damaged self. Thus, CD14
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has broad upstream regulatory functions on the sensor systems
of innate immunity.
Complement represents another important integral danger-
sensing and effector arm of innate immunity, and uncontrolled
activation involves all three complement pathways during sepsis
(16). Such systemic activation of complement and accompanying
release of anaphylatoxins (C3a and C5a) is potentially harmful
(17). The most potent proinflammatory anaphylatoxin, C5a, is
suggested to play a particularly important role in adverse clinical
effects during sepsis (18, 19).
Although TLRs and complement are often considered discrete
entities, an emerging body of evidence indicates that these key
innate defense systems are interconnected by extensive cross-talk
(20–23). The consequence of this interplay, which includes re-
dundancy, synergism, and antagonism, suggests inhibiting only
complement or TLRs may be insufficient to control inflammation.
We have previously demonstrated broad anti-inflammatory effects
by simultaneously inhibiting both CD14 and complement (24–29).
In this study, we document the efficacy of C5 and CD14 inhibition
on the systemic inflammatory response, morbidity, and survival of
mice subject to polymicrobial sepsis.
Materials and Methods
Ethics and study approval was obtained from the University of Ulm
Committee on Use and Care of Animals, approval number 988.
Coversin
Coversin, the recombinant Ornithodoros moubata C inhibitor, which pre-
vents activation of C5, is a 16.8-kDa recombinant protein produced
as described (30). Coversin was a kind gift from Volution Immuno-
Pharmaceuticals. The dose-dependent in vivo effect of coversin was
studied by giving mice a single i.v. or i.p. injection of coversin (0–100 mg/
mouse) (Supplemental Fig. 1A). Blood was collected via cardiac puncture
1 h after injection and the serum tested in a hemolytic assay with sheep
erythrocytes sensitized with mouse complement assay reagent (Comptech,
Tyler, TX) according to the manufacturer’s protocol. Briefly, serum was
incubated with mouse complement assay reagent–sensitized erythrocytes
for 30 min at 37˚C. The degree of lysis, which is directly related to acti-
vation of C5, was determined at 405 nm and related to 100% lysis control.
The results confirmed that the doses used in the present studies completely
neutralized C5 and thus blocked complement-mediated C5a and C5b-9
generation.
Anti-CD14
The anti-mouse CD14 Ab clone biG 53, produced in CD14 knockout (KO)
mice, exists in different isotypes and inhibits binding of LPS to CD14. The
IgG2a isotype was purchased from Biomedtec (Greifswald, Germany) and
cleaved into F(ab9)2 (Genovis, Lund, Sweden). The F(ab9)2 was highly pure
as determined by SDS-PAGE. The functional activity of biG 53 F(ab9)2
was tested in vitro. Immortalized mouse macrophages cultivated in DMEM
(Invitrogen, Carlsbad, CA) with 10% FCS (Lonza, Basel, Switzerland)
were incubated with a final concentration of 10 mg/ml anti-CD14 F(ab9)2
for 10 min prior to incubation with ultrapure LPS (Invivogen, Toulouse,
France). Twenty-four hours later, TNF was quantified in supernatants by
ELISA (R&D Systems, Minneapolis, MN). The F(ab9)2 fragment effi-
ciently abolished LPS-induced TNF production (Supplemental Fig. 1B).
The dose needed for the in vivo experiments to attenuate LPS-induced
cytokines was then tested and 100 mg/mouse selected for the subsequent
CLP experiments. A F(ab9)2 control fragment from an irrelevant control
Ab was purchased from Diatec Monoclonals (Oslo, Norway).
Analysis of inflammatory biomarkers
Twenty-three cytokines, including chemokines and growth factors, were
measured by a multiplex assay from Bio-Rad (Hercules, CA). The assay
included the following analytes: IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-6,
IL-9, IL-10, IL-12 p40, IL-12 p70, IL-13, IL-17, eotaxin (CCL11), G-CSF,
GM-CSF, IFN-g, keratinocyte chemoattractant (CXCL1), MCP-1 (CCL2),
macrophage inflammatory protein-1a (MIP-1a; CCL3), MIP-1b (CCL4),
RANTES (CCL5), and TNF. The analysis was preformed according to
the manufacturer’s instructions. Myeloperoxidase (MPO) was analyzed by
ELISA (Hycult Biotech, Uden, The Netherlands).
Induction of polymicrobial sepsis by CLP
Specific pathogen-free adult male mice, strain C57BL/6 (20–25 g in body
weight; Charles River Laboratories, Munich, Germany), were used. Ex-
perimental sepsis was induced by the CLP procedure as previously de-
scribed (12). In brief, mice were anesthetized with a 2.5% sevoflurane
(Sevorane; Abbott, Wiesbaden, Germany) and 97.5% oxygen mixture under
a continuous flow of 0.5 l/min at a fraction of inspired oxygen of 1.0 via an
inhalation mask. The mice were placed in supine position and their abdo-
mens shaved. Before surgery, mice received buprenorphine 0.01 mg/kg body
weight s.c. for adequate analgesia and every 12 h in the follow-up. An ab-
dominal midline incision of 1 cm was made to expose the cecum. The cecum
was ligated by 75% and punctured twice with a 21-gauge (0.723-mm) needle
to induce a high-grade sepsis in accordance with Rittirsch et al. (12). The
abdominal incision was closed in layers. In sham-operated controls, lapa-
rotomy was performed in a similar fashion, but the cecum was neither li-
gated nor punctured. Two separate studies were performed to measure the
inflammatory response (24 h) and the survival (10 d), respectively.
Inflammatory study
Mice were allocated to five groups (n = 8/group): 1) the coversin-treated
group received 300 mg coversin/mouse at CLP and 6 h after; 2) the anti-
CD14–treated group received 100 mg anti-CD14 F(ab9)2/mouse; 3) the
combined coversin and anti-CD14 group received the same doses as the
individual groups; 4) the positive control CLP group; and 5) the sham
group received Dulbecco’s PBS (DPBS). All groups received the same
volume (i.e., 200 ml i.v. at CLP and at 6 h). After sacrifice (24 h after CLP),
blood was obtained by heart puncture and serum separated at 4˚C and then
stored at 280˚C until analyzed in one batch.
Survival study
Twelve animals were allocated to each of five groups: 1) the coversin-treated
group received 100 mg coversin in 300 ml DPBS i.v. directly after CLP,
and, in addition, 200 mg coversin (in 300 ml DBPS) was given i.p. 24, 48,
72, 96, 120, and 144 h after CLP; and 2) the anti-CD14 group received
100 mg anti-CD14 F(ab9)2 (in 300 ml DPBS) i.v. as a single shot immediately
after CLP and thereafter i.p. every 24 h for 6 d. Thereafter, 300 ml DPBS
was given i.p. every 24 h after CLP to ensure equal volume loading to the
groups. 3) The combined coversin and anti-CD14 group underwent the
coversin protocol with the addition of 100 mg anti-CD14 F(ab9)2 in the first
injection; 4) the vehicle group (positive CLP control group) received 100 mg
control F(ab9)2 fragment (in 300 ml DPBS) i.v. immediately after CLP,
followed by the 300 ml DPBS i.p. applications at the given time points; and
5) sham animals (negative CLP control group) received only injections
with 300 ml DPBS at each given time point. Mice were not given anti-
biotics or specific fluid resuscitation. Survival rates were determined over
a 10-d (240-h) period, with clinical assessment (weight, mobility, and
eyelid motility) every 8 h for the first 48 h and every 12 h thereafter to day
10. All mice had unrestricted access to food and water.
Statistics
Cytokine readouts in the inflammatory study (Figs. 1–3) were compared
using one-way ANOVA with post hoc Dunnett’s correction for multiple
testing. In the survival study (Fig. 4), median survival time after surgery
was calculated by Hodges-Lehmann estimator. Survival times between
intervention groups were compared using the log-rank test. The overall
hypothesis “survival is the same in all four groups” was tested as the first
level of an a priori–ordered hypotheses. This hypothesis was rejected
(p = 0.0001). The second level of the a priori–ordered hypotheses had three
specific hypotheses. On this second level, p values were adjusted with the
Bonferroni-Holm procedure for multiple testing. The three specific hy-
potheses were differences among: 1) active therapy groups versus the un-
treated positive control group; 2) monotherapies of coversin or anti-CD14
versus combination thereof; and 3) monotherapy of coversin versus mon-
otherapy of anti-CD14. These three specific comparisons are independent;
each of them deliver truly new information. Morbidity scores in the sur-
vival analysis (Table I) were compared using a linear mixed-effects model
with treatment and interaction of treatment and time as fixed effects and
subject number as a random effect. All pairwise comparison among groups
was corrected for multiple testing using the Bonferroni-Holm procedure.
Results
Activity of coversin and anti-CD14 F(ab9)2
Coversin and the anti-CD14 Ab (clone biG 53) are known to
neutralize mouse C5 and CD14, respectively. For the purpose of
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this study, the dose of coversin needed to completely neutralize C5
when administered i.v. and i.p. was examined in vivo (Supplemental
Fig. 1A). The dose used in the subsequent CLP experimental proto-
cols was in sufficient excess to completely prevent complement-
mediated hemolysis. To avoid adverse effects of whole IgG, we
used F(ab9)2 fragments of anti-CD14. To quality control this prep-
aration, we examined the functional activity by testing the inhibi-
tory effect on LPS-induced TNF production by mouse macrophages
(Supplemental Fig. 1B). The functional effect was confirmed to be
preserved in the F(ab9)2 fragment.
In vivo studies
We first aimed to investigate the initial cytokine storm induced by
CLP polymicrobial sepsis. This study included a broad panel of
inflammatory biomarkers and was designed as a separate protocol
to ensure sufficient serum for analysis of the initial (24 h) in-
flammatory response and not interfere with the results of a survival
study due to complications during blood sampling and loss of
circulating blood volume.
Effects of C5 and CD14 blockade on the early cytokine storm
The four groups of animals undergoing CLP and the sham group
comprised eight animals each.Within 24 h, defined as the end of the
experiment and reflecting the initial inflammatory cytokine storm,
three mice died in the positive control group, two in the anti-CD14,
and none in the sham, coversin, or combined groups. Thus, the
number of animals included in the serum measurements for these
groups was five, six, eight, eight, and eight, respectively.
We examined 24 inflammatory markers using an assay for the
granulocyte activation marker MPO and a multiplex kit to assay 23
selected cytokines including ILs, chemokines, and growth factors.
The majority of the biomarkers (22 of 24) increased substantially
and significantly (p, 0.05 to,0.001) in the CLP-positive control
group compared with the sham group (Figs. 1, 2, 3). Two in-
flammatory markers (IL-9 and G-CSF) were not altered and ex-
cluded from further analysis.
We then tested the inhibitory effect of coversin, anti-CD14, and
the combination thereof on the 22 biomarkers that increased in the
CLP-positive group (Figs. 1–3). The quantitative inhibition was
substantial for both single and combined regimens (Supplemental
Table I). Single inhibition with coversin significantly inhibited 19
of 22 (not IL-6, CXCL1, and MPO), and single inhibition with
anti-CD14 significantly inhibited 20 of 22 markers (not IL-6 and
CXCL1). Notably, IL-6 (Fig. 1) and CXCL1 (Fig. 3), which were
not significantly inhibited by single treatment, were significantly
inhibited by the combined treatment. All 22 inflammatory markers
were significantly inhibited by the double blockade; inhibition
of CCL2 and CCL4 was particularly pronounced, and essentially
ablated, compared with single blockade (Fig. 2).
Effects of C5 and CD14 blockade on mortality
The positive results of the inflammatory study prompted us to
design a survival study with a 10-d observation period. The same
treatment groups were included, and the numbers were increased
from 8 to 12 mice in each group. Furthermore, the positive control
CLP group received a control F(ab9)2 fragment instead of buffer
control to exclude any nonspecific effects of anti-CD14 F(ab9)2 on
survival. Animals were given negative control F(ab9)2 or coversin
and/or anti-CD14 F(ab9)2 i.v. immediately after CLP and there-
after i.p. every 24 h for 6 d. Mice did not receive antibiotics or
fluid resuscitation.
All animals in the sham group were alive at the end of the study
(240 h; Fig. 4). In the positive control CLP group, all animals died
within 42 h (median survival 36 h). The three treatment regimens,
anti-CD14, coversin, and the combination thereof, considered
together increased survival significantly (median survival 36, 48,
and 96 h, respectively; p = 0.0106). Effect of single inhibitions
did not differ significantly from each other (p = 0.16), whereas
combined inhibition lead to a significant increase in survival in
comparison with single intervention (p = 0.0012).
Effects of C5 and CD14 blockade on morbidity
In addition to survival, the following clinical signs were recorded:
weight, mobility, and eyelid motility. Mean weight (gram) de-
creased modestly from the start of the experiment to the death of
the last animal in each of the CLP groups (positive control CLP
group: 23.4–21.7; anti-CD14 group: 24.1–22.3; coversin group:
24.2–20.3; and the combined group: 23.9–22.3), but not in the sham
group (23.0–23.2). Mobility and eyelid motility were scored, and
all data are presented in Table I. Full mobility and eyelid motility
(score 2) persisted throughout the experiment in the sham group.
Both single inhibitions showed a delay in clinical impairment
FIGURE 1. Inflammatory markers I. Serum IL-1a, IL-1b, IL-2, IL-3,
IL-4, IL-5, IL-6, and IL-10 increased significantly after 24 h in untreated
CLP mice (n = 5) as compared with sham mice (n = 8). Single treatment
with coversin (n = 8) or anti-CD14 (n = 6) significantly inhibited all
biomarkers except IL-6. Combined treatment (n = 8) significantly inhibited
all biomarkers. Significance compared with CLP positive control: *p ,
0.05, **p , 0.01, ***p , 0.001. aCD14, anti-CD14.
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during the first 24 h, but declined afterward and were thus not
significantly different to untreated controls over the whole ob-
servation period. The animals subjected to double blockade showed
significantly better mobility (p , 0.001 in comparison with posi-
tive control and single anti-CD14 treatment and p = 0.027 in
comparison with single coversin treatment) and eyelid motility
(p , 0.001 in comparison with positive control and single anti-
CD14 treatment and p = 0.012 in comparison with single coversin
treatment) throughout the whole observation period (Table I).
Discussion
The present study was designed to examine the efficacy of the
combined C5 and CD14 blockade regimen in a murine model of
CLP-induced sepsis, which better mimics human sepsis compared
with models using i.v. infusion of whole bacteria or LPS (31). We
demonstrate that combined inhibition of these key molecules,
belonging to two main pattern recognition receptor (PRR) sys-
tems, exerts a profound and broad-acting anti-inflammatory effect
on numerous biomarkers generated during polymicrobial sepsis.
Importantly, double blockade also significantly increased the
survival and clinical score of septic animals compared with single
inhibition of either C5 or CD14, which on their own had no effect
on survival in this severe model. This new treatment regimen,
targeting upstream recognition molecules of innate immunity that
are triggered by infection, appears promising when compared with
earlier work specifically targeting downstream mediators of in-
flammation, such as the cytokines TNF and IL-1b (32, 33).
The innate immune system serves as a first line of defense
against invading pathogens and contains various PRRs, which
recognize evolutionarily conserved structures on pathogens, the
pathogen-associated molecular patterns (PAMPs) and damage-
associated molecular patterns (DAMPs), which are released
from self-cells during sepsis. The TLRs and the complement
system are among the first PRR systems to be activated (34–36).
Upon activation, the TLR4/CD14/MD2 complex triggers the
production of several proinflammatory cytokines, such as IL-1b,
IL-6, IL-8, TNF, MIP-1a, and MIP-1b (37), and even causes the
release of neutrophil extracellular traps (38).
CD14 is a particularly important molecule for LPS-induced
inflammation. Studies have shown that absence or blocking of
CD14 protected mice, rabbits, and monkeys from organ damage
and death after LPS infusion (39–41). By contrast, mice over-
FIGURE 2. Inflammatory markers II. Serum IL-12p40, IL-12p70, IL-13,
IL-17, CCL2 (MCP-1), CCL3 (MIP-1a), CCL4 (MIP-1b), and CCL5
(RANTES) increased significantly after 24 h in the untreated CLP mice (n =
5) as compared with the sham mice (n = 8). Single treatment with coversin
(n = 8) or anti-CD14 (n = 6), as well as combined treatment (n = 8) sig-
nificantly inhibited all biomarkers. Significance compared with CLP posi-
tive control: *p , 0.05, **p , 0.01, ***p , 0.001. aCD14, anti-CD14.
FIGURE 3. Inflammatory markers III. Serum CCL11 (eotaxin), CXCL1
(keratinocyte chemoattractant [KC]), IFN-g, GM-CSF, TNF, and MPO in-
creased significantly after 24 h in the untreated CLP mice (n = 5) as com-
pared with the sham mice (n = 8). Coversin (n = 8) significantly inhibited all
biomarkers except CXCL1 and MPO. Anti-CD14 (n = 6) significantly
inhibited all biomarkers except CXCL1. Combined coversin and anti-CD14
significantly inhibited all biomarkers. Significance compared with CLP
positive control: *p , 0.05, **p , 0.01, ***p , 0.001. aCD14, anti-CD14.
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expressing CD14 were more sensitive to LPS-induced shock than
normal animals (42). Furthermore, blockade of CD14 in humans
almost completely inhibited the proinflammatory cytokine release
induced by i.v. injection of LPS (43). This is in line with our
previous study in a pig model of Gram-negative sepsis, which
showed that inhibition of CD14 efficiently attenuated the proin-
flammatory cytokine response and granulocyte activation (44).
The Escherichia coli–induced cytokine response in human whole
blood was also greatly abrogated by a CD14-neutralizing Ab (26).
In the current study of polymicrobial sepsis, inhibition of CD14
significantly inhibited the CLP-induced release of various in-
flammatory markers indicative for a robust systemic and CD14-
dependent inflammatory response. This underscores the broad
upstream regulatory function of CD14 and implies mechanisms of
action not exclusively limited to TLR4 and LPS. However, the
overall survival rate was not affected by single CD14 inhibition,
suggesting that harmful physiological effects resulting from the
polymicrobial challenge were insufficiently negated by CD14
blocking strategies alone. Ebong et al. (45) also found that CD14
KO mice displayed a 2–4-fold downregulation of pro- and anti-
inflammatory cytokines in response to CLP. However, CD14 KO
and control animals did not show differences in activity levels,
temperature, body weight, or survival rate after CLP. This might
be due to the fact that the majority of microorganisms released by
CLP are Gram-negative Bacteroides and some minor populations
of Gram-positive bacteria (46) in which LPS might play a less
predominant role (47).
The complement system represents an ancient PAMP- and
DAMP-sensing and transmission system that translates various
danger signals to an early fluid-phase and cellular response,
clinically evident as systemic inflammatory response syndrome
(SIRS). During development of SIRS and sepsis, there is an early
activation of complement via different pathways and perhaps via
activated coagulation and fibrinolysis factors (48, 49), leading to
generation of complement activation products, circulating C5a
receptors, complement consumption, and development of com-
plementopathy (50), similar to the development of sepsis-induced
coagulopathy. In the experimental setting of both mono- and
polymicrobial sepsis, there are multiple reports that control of
complement at the level of C3 (e.g., by compstatin) or C5 (e.g., by
anti-C5a Abs) results in improved molecular and cellular func-
tions, amelioration of the classical signs of coagulopathy, immune
and organ dysfunction, and improved survival (18, 51, 52).
The crucial involvement of C5 in human inflammation has been
closely studied using whole blood from C5-deficient humans (28).
Several interactions exist between the complement and the coag-
ulation cascades, favoring their reciprocal activation (49). Tar-
geting the terminal complement pathway, C5 or its receptor(s),
does not affect immunoprotective and immunoregulatory func-
tions of upstream C3 activity but does offer significant anti-
inflammatory potential due to the many important biological
roles of C5a (53). We previously demonstrated that coversin is
a potent C5 inhibitor in pigs as well as in humans, decreasing
E. coli–induced cytokine release in whole blood (54). Furthermore,
in a porcine model of E. coli–induced sepsis, coversin attenuated
central proinflammatory cytokines such as TNF and IL-6 and ef-
ficiently reduced thrombogenicity by reducing the expression of
tissue factor (29). The present study demonstrates that coversin
led to a significant decrease of almost all tested inflammatory
markers. However, as seen for single CD14 blockade, in this
severe septic challenge, survival rate was not improved by com-
plement inhibition alone. This is consistent with the broad-
spectrum PAMPs and DAMPs that are released and cause
immune activation during polymicrobial sepsis (12). When com-
paring cytokine inhibition with mortality rate, it should be noted
that the blood samples for cytokine analysis were obtained at
a single time point (24 h). In this study, it was not possible to
follow cytokine levels throughout the survival experiment, and it
is possible that cytokine patterns after .24 h might have better
reflected the differential mortality observed in the different treat-
ment groups. It is also worth noting that the concentration of
inflammatory mediators in plasma mirrors the inflammatory
condition without revealing the local inflammatory state. Thus, the
increased survival obtained by the combined inhibition may be
caused by a differential activity at the effector sites, for example
within specific organs, as recently shown with anti-CD14 in
a model of E. coli–induced sepsis in pigs (55).
Although TLRs and the complement cascade are coactivated
upon pathogen invasion, they were for a long time considered
distinct components of the innate immune system. However, recent
studies indicate considerable cross-talk between complement and
TLRs, revealing that they can compensate, synergize, or antagonize
each other. TLR activation and pre-exposure to TLR agonists can
increase cell sensitivity toward C5a both in vitro and ex vivo (22)
and augment the C5a-mediated proinflammatory responses (23).
Other studies revealed that TLR activation by LPS could addi-
tionally enhance complement protein synthesis (e.g., factor B) and
effector functions (21, 56). Bidirectionality of the TLR–C5aR inter-
action is supported by the finding that complement activation in
DAF2/2 mice, which exhibit enhanced levels of complement depo-
sition on cell surfaces, markedly increased TLR4-induced cytokine
production. This effect was mainly C5aR mediated and involved
the MAPKs ERK1/2 and JNK, possibly representing key connect-
ing molecules between the complement and TLR pathways (57).
The synergistic interactions between C5 and TLRs may help
to combat infections, but may also lead to an excessive proin-
flammatory response (20). Our current data do not identify what
are the harmful responses that are better controlled by the com-
bined therapy. We note, however, that only the dual- and not
single-blockade treatments significantly inhibited formation of IL-6,
which previously has been reported to be negatively associated with
sepsis, both in the murine CLP model and human sepsis (58–60).
The beneficial effect of the double blockade in the current study
is in line with previous results from our group demonstrating
FIGURE 4. Survival study. Twelve animals were allocated to each of the
following groups and observed for 10 d (240 h): CLP with positive control
F(ab9)2 (black line), sham (dotted line), anti-CD14 (yellow line), coversin
(red line), and combined coversin and anti-CD14 (blue line). Kaplan-Meier
plot shows survival in each of the groups. Overall survival in all treatment
groups combined compared with the CLP positive control was significant
(p = 0.016), and survival in the combined group was significantly increased
compared with the single therapies considered together (p = 0.0012),
which were not significantly different from each other (p = 0.16).
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a significantly more pronounced effect of double blockade com-
pared with single blockade of CD14 and complement, even when
the inflammation is predominantly LPS and therefore CD14 de-
pendent (61). In the earlier study using a porcine model of E. coli–
induced sepsis, inhibition of C5 and CD14 attenuated inflamma-
tion and thrombogenicity and delayed hemodynamic changes
(29). In the current study, it is tempting to suggest that the com-
bined inhibition may have had similar effects on thrombogenic
and hemodynamic parameters, which may explain the beneficial
effect of combined inhibition on survival.
A limitation of the current study is the use of mice. This CLP
model is, however, generally accepted to represent a clinically
relevant model to investigate SIRS and organ dysfunction caused
by polymicrobial sepsis because it combines tissue trauma caused
by the laparotomy, cell necrosis due to cecum ligation, and in-
fection from leakage of endogenous intestinal microbial flora into
the peritoneum (12). Translocation of enteric bacteria into the
circulation triggers SIRS and leads to profound upregulation of
various inflammatory mediators. Studies of the inflammatory re-
sponse and bacterial load in the organs would provide important
information of the pathophysiology and the response to the double
blockade, and we intend to investigate these aspects in future
studies.
Simultaneous suppression of pro- and anti-inflammatory media-
tors could have a negative effect on outcome of sepsis; however,
synchronous downregulation of anti- (e.g., IL-10) and proin-
flammatory (e.g., IL-6) cytokines caused by double inhibition of
complement and CD14 not only improved clinical parameters but
also survival rate. This supports the new paradigm that a dimin-
ished magnitude and duration of both the pro- and anti-inflammatory
genetic storm can beneficially influence the clinical course of pa-
thologies, as recently shown in neutrophils during endotoxemia and
after tissue trauma in humans (62).
In a clinical setting, many septic patients are admitted to the
hospital at a stage of the disease at which it is difficult to reverse the
pathological progress, even after intensive resuscitation, including
Table I. Clinical data (mobility and eyelid movement scores) from the survival CLP study
Hours Days
0 8 16 24 32 40 2 2 to 3 3 to 4 4 to 5 5 to 6 6 to 7 7 to 8 8 to 9 10
Mobilitya
Sham
2 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Positive control
2 12 12 4 0 0 —b
1 0 0 8 2 0 —
0 0 0 0 4 1 —
Anti-CD14
2 12 12 12 4 2 2 —
1 0 0 0 5 2 1 —
0 0 0 0 0 0 0 —
Coversin
2 12 12 12 7 4 4 2 1 1 —
1 0 0 0 2 3 3 1 1 0 —
0 0 0 0 0 0 0 1 0 0 —
Combined
2 12 12 12 7 7 7 8 6 4 4 0 0 0 0 0
1 0 0 0 4 1 1 0 2 2 1 4 3 2 2 1
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Eyelidsc
Sham
2 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Positive control
2 12 0 0 1 0 —
1 0 12 8 2 0 —
0 0 0 4 3 1 —
Anti-CD14
2 12 12 12 4 1 1 —
1 0 0 0 4 2 2 —
0 0 0 0 1 1 0 —
Coversin
2 12 12 12 7 4 4 2 1 1 —
1 0 0 0 2 3 3 1 1 0 —
0 0 0 0 0 0 0 1 0 0 —
Combined
2 12 12 12 8 8 8 8 8 6 4 4 3 2 2 1
1 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
Number of animals for each score in each group are indicated over time. Study groups (n = 12/group): sham (operation without CLP), positive control (CLP with isotype
control Ab), anti-CD14 (anti-CD14 treatment), coversin (coversin treatment), and combined (anti-CD14 and coversin treatment).
aMobility score: 2, spontaneous mobility; 1, provoked mobility; 0, no mobility.
bDeaths (—): all animals in the actual group were dead at this time point.
cEyelid motility score: 2, open; 1, open by touching; 0, closed.
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antibiotic therapy and early goal-intensive care treatment. In our
model, we did not include any rescue treatment, because the aim of
the study was to investigate the effect of complement and CD14
inhibition, as a proof of concept, not being interfered by rescue
therapy. Because we documented a significant effect on both
morbidity and mortality in this severe model, we will aim to study
this therapeutic regimen in a CLP rescue model (63) in future
experiments. It is tempting to speculate that double blockade
combined with antibiotic and intensive resuscitation would im-
prove survival even further.
Complement inhibitors are already in clinical use for certain
rare diseases. A number of diseases are on the list of possible
future candidates for complement therapeutics and several target
molecules are candidates for inhibition (64). The complement
inhibitor of choice will depend on the pathophysiology of the disease.
Some inhibitors work in both animal models and humans, like
the coversin used in this study. In contrast, the anti-CD14 Abs
are frequently species specific. Thus, we recently produced a
recombinant human-specific anti-CD14 IgG2/4 chimeric Ab that
showed no Fc-mediated effector function, but efficiently neutral-
ized CD14 (65).
In conclusion, the present in vivo study demonstrates that the
combined C5 and CD14 inhibition significantly improves systemic
inflammation, clinical signs, and survival rate in a clinically rel-
evant model of polymicrobial sepsis. Thus, the combined inhibi-
tion of the complement and TLR pathway represents a most
promising therapeutic approach to improve outcomes for patients
with polymicrobial sepsis.
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